Solid Biosciences Secures FDA Rare Pediatric Disease Designation for Novel Friedreich's Ataxia Gene Therapy
Key Insights
Solid Biosciences received FDA Rare Pediatric Disease and Fast Track designations for SGT-212, a dual-route gene therapy targeting Friedreich's ataxia (search).
SGT-212 represents the only gene therapy in development using both intradentate nucleus and intravenous delivery routes to restore frataxin (search) protein levels.
The designation provides potential access to a pediatric priority review voucher and enhanced FDA engagement for the FALCON Phase 1b trial currently screening participants.
Solid Biosciences Inc. (Nasdaq: SLDB) announced it has received Rare Pediatric Disease designation from the U.S. Food and Drug Administration for SGT-212, the company's investigational gene therapy for Friedreich's ataxia (search) (FA). The designation, combined with Fast Track status granted earlier this year, positions the dual-route gene therapy as a potentially accelerated pathway to market for patients with this devastating rare disease.
Dual-Route Gene Therapy Approach
SGT-212 is designed as a recombinant AAV-based gene replacement therapy that delivers full-length human frataxin (search) (FXN) via two distinct administration routes. The treatment utilizes an intradentate nucleus (IDN) infusion using an FDA-approved, stereotactic, precision MRI-guided device, followed by an intravenous (IV) infusion to increase therapeutic FXN levels in the cerebellar dentate nuclei and cardiomyocytes, respectively.
"SGT-212 is the only dual route gene therapy in development to treat Friedreich's ataxia (search)," according to the company's announcement. Targeted delivery to the dentate nuclei will be confirmed in real time via gadolinium, an MRI-enhancing contrast agent. The restoration of FXN levels is expected to repair the underlying mitochondrial dysfunction in neurons and cardiomyocytes to address neurologic, cardiac and systemic manifestations of the disease.
Regulatory Advantages and Clinical Progress
The Rare Pediatric Disease designation provides Solid Biosciences with the potential to receive a pediatric priority review voucher (PRV) upon approval, which can expedite the review for future Biologic License Applications. The PRV may be redeemed for priority review of another marketing application or may be sold or transferred to other sponsors.
"Receiving Pediatric Rare Disease designation marks another significant milestone for our Friedreich's ataxia (search) program, SGT-212," said Jessie Hanrahan, Ph.D., Chief Regulatory & Preclinical Operations Officer of Solid Biosciences. "Together with the Fast Track designation granted earlier this year, it recognizes our dual-route clinical approach for FALCON, our first-in-human trial, which is now screening participants, as an important first step in meeting an unmet need for FA."
The FALCON Phase 1b clinical trial is currently underway with participant screening in progress, representing the first-in-human study of this dual-route approach.
Addressing Critical Unmet Medical Need
Friedreich's ataxia (search) is an inherited, life-threatening, degenerative multisystem disease caused by defects in the frataxin (search) gene that disrupt production of the frataxin protein, a mitochondrial iron-binding protein involved in essential cellular processes, including energy production. The disease causes progressive nervous system damage, movement problems, and cardiac dysfunction, with cardiac complications identified as the primary cause of death.
FA impacts approximately 5,000 people in the United States and 15,000 in Europe. Currently, there are no treatments that provide a cure or halt disease progression, highlighting the significant unmet medical need that SGT-212 aims to address.
Broader Pipeline Development
Solid Biosciences is advancing a comprehensive portfolio of gene therapy candidates targeting rare neuromuscular and cardiac diseases. Beyond SGT-212, the company's pipeline includes SGT-003 for Duchenne muscular dystrophy (search), SGT-501 for catecholaminergic polymorphic ventricular tachycardia (search) (CPVT), and SGT-601 for TNNT2-mediated dilated cardiomyopathy (search), among other fatal genetic cardiac diseases.
The company is also developing innovative libraries of genetic regulators and enabling technologies with potential to significantly impact gene therapy delivery across the industry. Founded by those directly impacted by Duchenne muscular dystrophy (search), Solid Biosciences maintains a patient-focused mission to improve the daily lives of patients living with devastating rare diseases.